Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
W. David Hardy, M.D., discusses the takeaway messages for HIV care providers after a recent research paper found that a third of all people living with HIV reported never discussing U=U with their provider.
Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.
Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
A Chicago survey of people over 60 finds high self-reported viral suppression rates—but also clear signs that people need help navigating a range of other physical and mental health concerns.
June 4, 2020: The latest on COVID-19 hospitalization among people with HIV; real-world success of hepatitis C treatment in coinfected patients with good health care; poverty and adherence in Canada's health system; demographic and socioeconomic factors associated with viral rebound.
Having to diagnose people with HIV again and again can take a mental toll on health care workers, as can hearing people’s traumas. But few health care workers process the vicarious trauma they experience.
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.